Clinical Trial

Optical Coherence Tomography Angiography Evaluation Of Patients Taking Hydroxychloroquine

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 13, 2026 (before its estimated August 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study aims to evaluate retinal and choroidal microvascular changes using optical coherence tomography angiography (OCTA) in patients receiving hydroxychloroquine therapy. Hydroxychloroquine is commonly used in the treatment of autoimmune diseases and may cause retinal toxicity with long-term use. OCTA is a non-invasive imaging modality that allows detailed assessment of retinal vascular changes.
Trial Details
NCT Number NCT07409740
Lead Sponsor Sohag University
Conditions Hydroxychloroquine Retinopathy
Enrollment 90 participants
Start Date 2026-02-01
Primary Completion 2026-08-01 (estimated)
Study Completion 2026-09-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-13